

NovaSterilis Inc. Awarded Contract for Supercritical Carbon Dioxide Equipment by US Army Natick Soldier Research, Development and Engineering Center (NSRDEC)

ITHACA, NY – January 2, 2011 - NovaSterilis, Lansing NY, is excited to announce they have been granted the contract by NSRDEC for a supercritical CO₂ unit to be utilized for research by the Combat Feeding Program. Supercritical CO₂ (SCCO₂), or the fluid phase of CO₂ occurs when CO₂ is at, or above, its critical pressure of 1099 PSI and temperature 31.1° C. Supercritical CO₂ has numerous current commercial applications including the decaffeination of coffee and extraction of botanicals from plants, and is gaining popularity because it is a non toxic, inexpensive and a renewable non polar solvent. NovaSterilis was awarded this contract based on proof of concept work performed at NovaSterilis by the Combat Feeding Program utilizing a Nova2200 unit. The Combat Feeding program is planning further research and product development utilizing the Nova2200 supercritical CO₂ unit.

The Nova2200 is a fully automated, programmable, computer controlled, network capable supercritical CO₂ unit that is commercially available. NovaSterilis manufactures the Nova2200 (20 liter chamber) unit and a larger Nova8800 (80 liter chamber) for the sterilization of biomedical material including but not limited to; allograft and xenograft tissue, tissue engineered material, bioengineered products, medical devices, active and inactive pharmaceutical ingredients, and other raw materials including food products.

“NovaSterilis is proud to be associated with this important and prominent research program and we look forward to assisting NSRDEC, we have extensive knowledge of the properties and applications of SCCO₂” states David C. Burns President CEO NovaSterilis. “We have introduced the biomedical community to the benefits of using SCCO₂ for terminal sterilization, now we have the opportunity to work with the best researchers at NSRDEC developing better tasting, healthier and safer food products for the women and men serving our country in the military.”

About NovaSterilis

NovaSterilis, incorporated in 2002, develops and commercializes applications for supercritical carbon dioxide. The initial commercial application, sterilization of biomedical materials, has resulted in two patents, the first US Patent 7108832 Sterilization Methods and Apparatus Which Employ Additive –Containing Supercritical CO₂ Sterilant and a second Patent 7,560,113 for creation and production of whole cell bacterial vaccines. Sterilization by nature is a destructive process and current terminal sterilization, or sterilization in final packaging, is dominated by radiation or ethylene oxide (EtO). Radiation degrades many materials, especially delicate products and biologic materials. EtO a toxic and carcinogenic gas has long term effects for process technicians and our environment. SCCO₂ sterilization provides the medical materials industry a safe, gentle, and environmentally friendly process. There are 4 tissue banks selling allograft tissue sterilized utilizing NovaSterilis technology and there are innovative medical device companies developing products utilizing our terminal sterilization technology.